Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:

 

Methadone treatment suppresses testosterone in opioid addicts

26.08.2014

Affects men but not women

Treatment for opioid addiction tampers with the testosterone levels of male but not female opioid users, McMaster University research has shown.

In a paper published today by the journal Scientific Reports, the researchers say addiction treatment may need to change to address the side-effect.

The study found men using methadone, which is used for opioid addiction treatment, have significantly suppressed testosterone levels of about a quarter of the testosterone of men not using opioids. In women using methadone for addiction treatment, testosterone levels were not significantly impacted, even considering the menstrual cycle.

Low testosterone in men has been associated with poor quality of life as well as erectile dysfunction, fatigue, and mood disturbances.

"We expect that treating testosterone deficiency will improve outcomes of methadone treatment for patients, including treatment response and retention," said Dr. Zena Samaan, principal investigator of the study.

"Doctors should also ensure the patients are being prescribed the lowest dose of opioids including methadone for effective treatment to minimize testosterone suppression."

She added that this is a particular issue in Canada, the second largest consumer of opioids in the world.

Dr. Samaan is an associate professor of the psychiatry and behavioural neurosciences department of McMaster's Michael G. DeGroote School of Medicine.

The study involved information from 231 patients with opioid dependence receiving methadone in Ontario, as well as 783 Ontarians not using opioids. It was funded by the Drug Safety and Effectiveness Network of the Canadian Institutes of Health Research and the McMaster Department of Psychiatry and Behavioural Neurosciences. The study was conducted by the Population Genomics Program of McMaster's Chanchlani Research Centre, and Ontario Addiction Treatment Centres.

For more information:

Veronica McGuire
Media relations
Faculty of Health Sciences
McMaster University
vmcguir@mcmaster.ca
905-525-9140, ext. 22169

Zena Samaan
Associate Professor,
Psychiatry and Behavioural Neurosciences
samaanz@mcmaster.ca

Veronica McGuire | Eurek Alert!
Further information:
http://www.mcmaster.ca

Further reports about: Health McMaster Neurosciences Psychiatry Treatment levels methadone testosterone

More articles from Health and Medicine:

nachricht Long-acting insulin is safer, more effective for patients with Type 1 diabetes
01.10.2014 | St. Michael's Hospital

nachricht Immunotherapy could stop resistance to radiotherapy
01.10.2014 | Cancer Research UK

All articles from Health and Medicine >>>

The most recent press releases about innovation >>>

Anzeige

Anzeige

Event News

BrainScaleS Conference: From Neurobiology to New Computer Architectures

25.09.2014 | Event News

17th European Health Forum Gastein: “Electing Health – The Europe We Want”

23.09.2014 | Event News

Future questions regarding data processing

22.09.2014 | Event News

 
Latest News

All directions are not created equal for nanoscale heat sources

01.10.2014 | Power and Electrical Engineering

Long-acting insulin is safer, more effective for patients with Type 1 diabetes

01.10.2014 | Health and Medicine

Microbes in Central Park soil: If they can make it there, they can make it anywhere

01.10.2014 | Life Sciences

VideoLinks
B2B-VideoLinks
More VideoLinks >>>